Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b pediatric epcoritamab trial in relapsed/refractory aggressive mature B-cell neoplasms
jRCT2041220067Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab in mature B-cell lymphoma, Burkitt lymphoma (BL), B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma and 2 more, sponsored by AbbVie Inc. Primary endpoints: Adverse events, Maximum concentration (Cmax) and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphomaBurkitt-like leukemia (BLL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2041220067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220067.